[1]曹绍华,王庆庆,张金冉△.索拉非尼联合卡培他滨治疗肝细胞肝癌疗效及对患者血清miR-212和miR-132水平的影响[J].陕西医学杂志,2020,49(5):615-618.
　CAO Shaohua,WANG Qingqing,ZHANG Jinran..Curative effect of sorafenib combined with capecitabine in treatment of hepatocellular carcinoma and its influence on serum miR-212 and miR-132 levels[J].,2020,49(5):615-618.
点击复制

索拉非尼联合卡培他滨治疗肝细胞肝癌疗效及对患者血清miR-212和miR-132水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年5期
页码:
615-618
栏目:
药物与临床
出版日期:
2020-05-05

文章信息/Info

Title:
Curative effect of sorafenib combined with capecitabine in treatment of hepatocellular carcinoma and its influence on serum miR-212 and miR-132 levels
文章编号:
DOI:10.3969/j.issn.10007377.2020.05.028
作者:
曹绍华; 王庆庆; 张金冉△
延安大学附属医院临床药学科(延安716000)
Author(s):
CAO Shaohua; WANG Qingqing; ZHANG Jinran.
Clinical Medicine of Affiliated Hospital of Yan'an University(Yan'an 716000)
关键词:
肝细胞肝癌;  治疗;  卡培他滨;  索拉非尼;  微小RNA-212;  微小RNA-132
Keywords:
Hepatocellular carcinoma;  Therapy;  Capecitabine;  Sorafenib;  microRNA-212;  microRNA-132
分类号:
R735.7
文献标志码:
A
摘要:
目的:观察索拉非尼联合卡培他滨治疗肝细胞肝癌(HCC)的疗效及对患者血清miR-212和miR-132水平的影响。方法:选取70例HCC患者,随机数表法分为两组,试验组35例给予索拉非尼联合卡培他滨治疗,对照组35例采取索拉非尼治疗。比较两组临床疗效、血清miR-212和miR-132水平,血清白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(INF-γ)水平、不良反应发生情况及1年生存率。结果:试验组疾病控制率为82.86%高于对照组60.00%(P<0.05); 治疗后,试验组的TNF-α水平低于对照组(P<0.05); 治疗后,试验组的miR-212、miR-132水平均高于对照组(P<0.05); 试验组患者手足综合征和恶心呕吐的发生率高于对照组(P<0.05),两组疲乏、贫血和白细胞下降的发生率相比无统计学差异(P>0.05); 试验组1年生存率为74.29%(26/35)高于对照组的51.43%(18/35),差异有统计学意义(P<0.05)。结论:索拉非尼联合卡培他滨治疗HCC患者,可提高疾病控制率,患者血清miR-212和miR-132水平升高,不良反应可耐受。
Abstract:
Objective:To observe the curative effect of sorafenib combined with capecitabine in treatment of hepatocellular carcinoma(HCC)and its influence on the levels of serum miR-212 and miR-132. Methods:A total of 70 HCC patients were enrolled and divided into two groups by random number table method,with 35 cases in each group. The experimental group was treated with sorafenib combined with capecitabine,while the control group was treated with sorafenib. The clinical curative effect,the levels of serum miR-212,miR-132,interleukin-2(IL-2),tumor necrosis factor-α(TNF-α)and interferon-γ(INF-γ),the occurrence of adverse reactions and 1-year survival rate were compared between the two groups. Results:The disease control rate of experimental group was higher than that of control group(82.86% vs. 60.00%)(P<0.05). After treatment,the TNF-α level in the experimental group was lower than that in the control group(P<0.05),while the levels of miR-212 and miR-132 were higher than those in the control group(P<0.05). The incidence of hand-foot syndrome,and nausea and vomiting in experimental group was higher than that in the control group(P<0.05). There was no significant difference in incidence of fatigue,anemia and leukopenia between the two groups(P>0.05). The 1-year survival rate of experimental group was higher than that of control group [74.29%(26/35)vs. 51.43%(18/35)](P<0.05). Conclusion:Sorafenib combined with capecitabine in treatment of HCC patients can improve disease control rate,increase the levels of serum miR-212 and miR-132. The adverse reactions can be tolerated.

参考文献/References:

[1] Lu Z,Zuo B,Jing R,et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models[J]. Journal of Hepatology,2017,67(4):739-748.
[2] Gardini AC,Conti F,Brillanti S,et al. Imbalance of neutrophils and lymphocyte counts can be predictive of hepatocellular carcinoma occurrence in hepatitis c-related cirrhosis treated with direct-acting antivirals[J]. Gastroenterology,2018,154(8):2281-2282.
[3] 赫崇军,李 清,熊六林,等.高强度超声体外聚焦热疗技术治疗254例中晚期肝癌的临床观察[J].中国急救复苏与灾害医学杂志,2007,2(3):150-152.
[4] Kudo M,Finn RS,Qin S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
[5] Zhang XP,Wang K,Wang M,et al.Transarterial chemoembolization(TACE)combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus:a systematic review and meta-analysis[J]. Oncotarget,2017,8(17):29416-29427.
[6] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J].European Journal of Cancer,2009,45(2):113-121.
[7] 俞南松,严培军,郑媛媛,等.射频消融联合索拉非尼治疗中晚期肝癌对患者肝功能的影响及疗效分析[J].中华全科医学,2018,16(5):754-756.
[8] Trevisani F,Brandi G,Garuti F,et al.Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation[J]. Journal of Cancer Research and Clinical Oncology,2017,144(2):403-414.
[9] Liu Y,Zhang XL,Li XF,et al.miR-212-3p reduced proliferation,and promoted apoptosis of fibroblast-like synoviocytes via down-regulating SOX5 in rheumatoid arthritis[J]. European Review for Medical & Pharmacological Sciences,2018,22(2):461-471.
[10] Zhao Y,Zhao R,Wu J,et al. Melatonin protects against Aβ-induced neurotoxicity in primary neurons via miR-132/PTEN/AKT/FOXO3a pathway:Melatonin on Aβ-induced neurotoxicity in primary neurons[J]. Biofactors,2018,44(6):609-618..
[11] Wang F,Wang J,Ju L,et al.Annals express:diagnostic and prognostic potential of serum miR-132/212 cluster in patients with hepatocellular carcinoma[J]. Annals of Clinical Biochemistry,2018,55(5):576-582.
[12] 侯悦悦,吴 穷,郑荣生.MicroRNAs在原发性肝癌中的研究进展[J].中华全科医学,2015,13(9):1514-1516.
[13] 毕丽华.替吉奥或紫杉醇联合索拉非尼治疗原发性肝癌的预后对比分析[J].解放军预防医学杂志,2018,36(5):647-649.
[14] 石洁琼,康马飞,李碧慧,等.全量或半量索拉非尼联合卡培他滨治疗肝细胞肝癌的临床观察[J].现代肿瘤医学,2018,246(12):90-93.
[15] 冯 跃.索拉非尼治疗肝细胞癌肺转移39例预后分析[J].肿瘤学杂志,2018,24(10):987-991.
[16] 郭 茜,齐秀恒,武振明,等.卡培他滨单药联合重组人血管内皮抑素(恩度)用于老年晚期结直肠癌一线化疗的研究[J].现代肿瘤医学,2017,25(6):921-923,924.

相似文献/References:

[1]孟 涛,刘锦波,王纪科,等.输尿管硬镜钬激光碎石与后腹腔镜上段输尿管切开取石治疗输尿管结石疗效对比研究*[J].陕西医学杂志,2020,49(2):162.
　MENG Tao,LIU Jinbo,WANG Jike,et al.Analysis of efficacy of holmium laser ureteroscopic lithotripsy and retroperitoneal laparoscopic ureterolithotomy on ureteral calculi[J].,2020,49(5):162.
[2]李延喜,郭世文△.微创手术对高血压基底节脑出血患者生活质量及脑功能恢复效果的影响研究[J].陕西医学杂志,2020,49(2):166.
　LI Yanxi,GUO Shiwen..Effect of minimally invasive surgery on the quality of life and brain function recovery in patients with hypertensive basal ganglia hemorrhage[J].,2020,49(5):166.
[3]谢江涛,苏永永,吴鹏昌,等.显微镜联合神经内镜治疗颅内前循环破裂动脉瘤疗效研究[J].陕西医学杂志,2020,49(2):205.
[4]张静雯,汪 宁,邱红霞,等.非布司他治疗早期糖尿病肾病合并高尿酸血症疗效及对患者肾功能影响研究*[J].陕西医学杂志,2020,49(2):209.
　ZHANG Jingwen,WANG Ning,QIU Hongxia,et al.Efficacy of febuxostat on early diabetic nephropathy with hyperuricemia and its effect on renal function[J].,2020,49(5):209.
[5]姜 萌,赵 鹏△.奥曲肽联合加贝酯治疗重症急性胰腺炎疗效及对患者血清细胞因子水平的影响[J].陕西医学杂志,2020,49(2):212.
　JIANG Meng,ZHAO Peng..Clinical efficacy of octreotide combined with gabexate in the treatment of severe acute pancreatitis and its effect on serum cytokine levels[J].,2020,49(5):212.
[6]薛佩妮,冯敏娟△,王惠琴.噻托溴铵粉联合糖皮质激素治疗慢性阻塞性肺疾病疗效及对患者生活质量评分的影响*[J].陕西医学杂志,2020,49(2):216.
　XUE Peini,FENG Minjuan,WANG Huiqin..Efficacy of tiotropium bromide combined with glucocorticoids in the treatment of COPD and its effect on patients' quality of life score[J].,2020,49(5):216.
[7]王瑶君,王 岩△.色甘萘甲那敏鼻喷雾剂治疗急性非化脓性中耳炎疗效及对患者血清miR-203a和miR-155的影响[J].陕西医学杂志,2020,49(2):220.
　WANG Yaojun,WANG Yan..The efficacy of Shuntuomin in the treatment of acute non-suppurative otitis media and its effect on serum miR-203a and miR-155[J].,2020,49(5):220.
[8]刘 阳,许汴菊△.醋酸亮丙瑞林微球在子宫腺肌病合并不孕患者行体外受精-胚胎移植治疗中的应用*[J].陕西医学杂志,2020,49(2):223.
　LIU Yang,XU Bianju..Application of Leuprolide acetate microsphere in the treatment of adenomyosis combined with infertility in patients undergoing IVF-ET[J].,2020,49(5):223.
[9]关艳杰.中重度宫腔粘连病因及治疗研究进展[J].陕西医学杂志,2020,49(2):254.
[10]蒙政初.吻合器痔上黏膜环切术联合缚扎术治疗重度环状混合痔疗效研究*[J].陕西医学杂志,2020,49(5):561.
　MENG Zhengchu..Therapeutic effect of procedure for prolapse and hemorrhoids combined with ligation in the treatment of severe circular mixed hemorrhoids[J].,2020,49(5):561.

更新日期/Last Update: 2020-07-28